Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Sold Off Sen. Cory A. Booker

Senator Cory A. Booker (Democratic-New Jersey) recently sold shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). In a filing disclosed on September 09th, the Senator disclosed that they had sold between $1,001 and $15,000 in Alnylam Pharmaceuticals stock on August 11th.

Senator Cory A. Booker also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 8/11/2026.
• Sold $15,001 – $50,000 in shares of McDonald’s (NYSE:MCD) on 8/11/2026.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/11/2026.
• Sold $1,001 – $15,000 in shares of JD.com (NASDAQ:JD) on 8/11/2026.
• Sold $100,001 – $250,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/11/2026.

Alnylam Pharmaceuticals Stock Up 0.5%

NASDAQ:ALNY opened at $248.68 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $33.28 billion, a P/E ratio of 46.22 and a beta of 0.31. The stock’s fifty day simple moving average is $254.43 and its 200-day simple moving average is $288.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the previous year, the firm earned ($0.51) earnings per share. The firm’s quarterly revenue was up 66.9% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ALNY shares. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Jefferies Financial Group boosted their price objective on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a “hold” rating in a report on Tuesday. JPMorgan Chase & Co. lowered their target price on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. BMO Capital Markets reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. Finally, Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $376.67.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. California State Teachers Retirement System lifted its position in shares of Alnylam Pharmaceuticals by 30,461.4% in the second quarter. California State Teachers Retirement System now owns 60,164,157 shares of the biopharmaceutical company’s stock worth $18,111,216,000 after purchasing an additional 59,967,294 shares in the last quarter. Norges Bank bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $895,816,000. Legal & General Group Plc acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at $278,321,000. Qube Research & Technologies Ltd bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth about $369,943,000. Finally, AQR Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 295.2% during the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after buying an additional 555,759 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Senator Booker

Cory Booker (Democratic Party) is a member of the U.S. Senate from New Jersey. He assumed office on October 31, 2013. His current term ends on January 3, 2027. Booker (Democratic Party) ran for re-election to the U.S. Senate to represent New Jersey. He won in the general election on November 3, 2020. Booker also ran for election for President of the United States. He did not appear on the ballot for the Democratic convention on August 18, 2020. Booker announced that he was running for president of the United States on February 1, 2019. He suspended his presidential campaign on January 13, 2020. Before being elected to the Senate, Booker served as the 36th mayor of Newark. He also served on the Newark City Council for the Central Ward. In September 2017, he was rated the third most liberal senator based on his voting record, according to The New York Times. Booker was born in 1969 in Washington, D.C., and grew up in Harrington Park, New Jersey. He attended Stanford University on a varsity football scholarship, receiving a B.A. in 1991 and an M.A. in 1992. Booker was a Rhodes Scholar at the University of Oxford, where he earned a graduate degree in history in 1994. He then attended Yale Law School, graduating with a J.D. in 1997. After completing his education, Booker moved into a public housing project in Newark, New Jersey, became a tenant organizer, and founded a nonprofit that provided legal assistance to low-income families. He was elected to the Newark City Council in 1998 and served there until 2002, when he ran unsuccessfully for mayor. The same year, he became a partner at Booker, Rabinowitz, Trenk, Lubetkin, Tully, DiPasquale & Webster. In 2006, Booker ran again for mayor of Newark and was elected with 72% of the vote. He served as mayor until 2013. On October 16, 2013, Booker won a special election to the U.S. Senate after the death of Sen. Frank Lautenberg (D). Booker was re-elected to the U.S. Senate on November 4, 2014. In 2016, Booker published a memoir titled United: Thoughts on Finding Common Ground and Advancing the Common Good.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).